Esophagus Cancer
114
29
37
36
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
5.3%
6 terminated out of 114 trials
85.7%
-0.8% vs benchmark
4%
5 trials in Phase 3/4
19%
7 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 36 completed trials
Clinical Trials (114)
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Proton Therapy for Esophageal Cancer
Endoluminal Vacuum Therapy to Prevent Anastomotic Leakage After Esophagectomy Due to Esophageal Cancer
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
Statewide Unified Network for Remote Intervention of Strength and Exercise
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Proton Beam Therapy in the Treatment of Esophageal Cancer
Mayo Clinic Upper Digestive Disease Survey
Retrospective Review of Esophageal Cancer at MSKCC
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging